Ganciclovir is an antiviral agent that is frequently used in critically ill patients with cytomegalovirus (CMV) infections. Continuous venovenous haemodiafiltration (CVVHDF) is a common extracorporeal renal replacement therapy in intensive care patients. Aim of this study was to investigate the pharmacokinetics of ganciclovir in anuric patients undergoing CVVHDF.
Introduction
Ganciclovir is a pro-drug nucleoside analogue that shows antiviral activity against members of the herpes group and in particular against human cytomegalovirus (CMV).
[1] It has proven therapeutic effect in treatment of several CMV related infections as retinitis, pneumonia, infections of the gastrointestinal tract, infections of the nervous system or prevention of the CMV disease in patients with AIDS or immunocompromised state following transplantation. [1] [2] [3] The risk of CMV infection is increased in critically ill patients due to requirement of mechanical ventilation, sepsis, immunodeficiency, transfusions and renal failure. [4] Ganciclovir is mainly excreted by the kidneys and can be found almost unchanged in the urine with an elimination half-life of 2-4 hours. Elimination is significantly prolonged in patients with renal impairment and its clearance decreases linearly with diminishing creatinine clearance. [5, 6 ] Therefore a dosage reduction is required in those patients. In patients with normal renal function a daily dosage of 10mg/kg body weight is recommended. Table 1 illustrates dosing recommendation for patients with impaired renal function adjusted by creatinine clearance as described in the summary of product characteristics. [7] Up to date no specific therapeutic exposure values for ganciclovir have been established. [8] However, viremia suppression was reported with ganciclovir exposure (area under the curve, AUC) of 40-50 mg·h/L. [9] Therefore an AUC > 50 mg·h/L has been used as target exposure. [10] In order to ensure deep tissue penetration and avoid underdosing in patients with life-threatening CMV-infection we analysed both, AUC > 50 mg·h/L and trough levels of 2 mg/L. A specific exposure may reduce toxicity and maintains the therapeutic effect.
Continuous venovenous haemodiafiltration (CVVHDF) is a common form of extracorporeal renal replacement therapy in critically ill patients with renal failure. The elimination of any given drug by continuous renal replacement therapy (CRRT) is dependent on different factors such as specific properties of the membrane (pore-size, filter surface area, adsorption, filter material), characteristics of the CRRT technique used (blood flow rate, ultrafiltration rate) or properties of the drug (volume of distribution, molecular charge, molecular weight and protein-binding). [11, 12] The low molecular weight of ganciclovir (255.2 daltons), high water solubility (3 mg/ml) and very low plasma protein binding (1-2%) are relevant factors in removal via CVVHDF. [3, 7] Pharmacokinetics (PK) of ganciclovir have been described in several studies. [1, 13, 14] However, there is a lack of pharmacokinetic data of ganciclovir administered during CVVHDF. Accordingly, there is no specific dosage recommendation for patients undergoing CVVHDF.
The aims of this study were (i) to investigate the pharmacokinetics of ganciclovir during CVVHDF in critically ill patients with suspected or proven CMV infection; (ii) to find potential predictive factors for dose individualization; and (iii) to establish a pharmacokinetic model of ganciclovir in order to evaluate different body weight-based dosage regimens (5 mg/kg/24h, 2.5 mg/kg/24h, 1.5mg/kg/12h) and individualized dosing via target-AUC to prevent under-or overexposure in patients with renal replacement therapy.
Materials and methods

Patient eligibility
This was a prospective open-label study. All patients at the age of 18 years and older, who were treated at an intensive care unit (ICU) and were prescribed ganciclovir as part of their required medical care due to suspected or proven CMV infection and who underwent CVVHDF for treatment of severe renal disease were eligible for this study. Exclusion criteria included age less than 18 years and other extracorporeal therapy than CVVHDF. The study protocol was approved by the local ethics committee.
Medication
All patients received 5 mg/kg ganciclovir in a 30 min infusion via a central venous line, different from the one used for CVVHDF.
Sampling and storage
Blood samples were drawn from the prefilter (arterial) and postfilter (venous) line of the extracorporeal circuit at 0, 30, 60, 90, 180, 360, 480 and 1440 minutes after finishing the infusion. Regarding tolerability and occurrence of haematological side effects, red blood cells (RBC), haemoglobin (HB), platelets (PLT) and white blood cells (WBC) were quantified on a daily basis during the treatment phase.
Ultradiafiltrate samples were taken from the outlet of the ultradiafiltrate compartment of the haemodiafilter at corresponding times.
All samples were centrifuged immediately and stored at -70°C until assayed.
Continuous venovenous haemodiafiltration
CVVHDF was performed using an AN 69 HF hollow fiber haemofilter (Prisma M100 Pre Set, Hospal Industrie, Meyzieu, France) with a membrane surface are of 0.9 m 2 . Dialyzers and lines were steam sterilized. The standard blood flow rate was 9 L/h, pre-dilution volume was infused at a rate of 1 L/h and dialysate rate was 1 L/h, as described previously. [15, 16] Net fluid balance was modified according to clinical requirements. No filter change occurred during study period.
Sample assay
The concentration of ganciclovir in serum and ultrafiltrate was measured by a high performance liquid chromatography (HPLC) using a Dionex "UltiMate 3000" system (Dionex Corp., Sunnyvale, CA). Briefly, after the addition of 200 µl of methanol to 100 µl of serum or ultrafiltrate, the samples were centrifuged (5000g for 5 min at 4°C), and 100 µl of the sample was injected onto a Hypersil BDS-C 18 column (5 µm, 250 × 4.6 mm I.D., Thermo Fisher Scientific, Inc, Waltham, MA), preceded by a Hypersil BDS-C 18 precolumn (5 µm, 10 × 4.6 mm I.D.) at a flow rate of 1 ml/min. Ganciclovir was monitored fluorimetrically at 278 nm (excitation) and 380 nm (emission). Mobile phase A consisted of potassium phosphate (50 mM, pH 3,0 with phosphoric acid) and heptanesulfonic acid (5 mM) and the mobile phase B consisted of methanol. Mobile phase was filtered through a 0.45 µM filter (HVLP04700, Millipore, Vienna, Austria). The gradient ranged from 3 % B (0 min) to 14 % at 30 min, kept constant at 14 % until 36 min, and finally decreased linearly to 3 % again at 37 min. The columns were allowed to re-equilibrate for 13 min between runs. Linear calibration curves were performed from the peak areas of ganciclovir to the external standard by spiking drug-free human serum and ultrafiltrate with standard solutions of ganciclovir (final concentrations ranging from 0.005 µg to 10 µl/ml). For this method the lower limit of quantification for ganciclovir was determined to be 5 ng/ml for ganciclovir in serum and ultrafiltrate. Intra-day values for ganciclovir ranged from 4.1 to 8.0 %, inter-day values from 4.9 to 9.3 % using ganciclovir concentrations of 0.01, 0.1, and 1 µg/ml.
Pharmacokinetic analysis
Pharmacokinetic analysis was performed in all patients after receiving a single dose of 5 mg/kg ganciclovir. The serum concentration-time curves of ganciclovir in plasma were adjusted to the data sets via nonlinear iterative least-square regression analysis. Curve modelling was performed using the two-compartment PK model with the program WinNonlin (vers. 5.1), Scientific
Consulting, USA). The following parameters were calculated: area under the concentration curve from 0 to 24 h (AUC 0-24 ) using the linear trapezoidal rule, total clearance (Cl tot ), volume of distribution (V), distribution half-life (t 1/2 α), elimination half-life (t 1/2 β). The sieving coefficient (S) was calculated as S = C UDF /C A . and intercompartmental clearance (Q). Interindividual variability was estimated for all PK parameters using an exponential error model. The residual error was described with a proportional error model. Covariates were not included in the model due to the small number of patients. Typical and individual PK parameters were estimated using the "FOCE" method in NONMEM ® . Model evaluation was performed using objective function value, goodness-of-fit plots, standard errors and visual predictive check.
Model-based simulations
With the final PK model three different simulation scenarios were performed with the study 
Monte Carlo simulation
In addition, ganciclovir plasma levels were simulated in four populations of 1000 patients using a Monte Carlo approach. The simulated datasets comprised seven ganciclovir administrations. A weight between 40-140 kg was randomly assigned to every simulated patient. Each population was characterized by a different dosing regimen (5 mg/kg/24h, 2.5 mg/kg/24h, 1.5 mg/kg/12 h and target-AUC adjusted dosing every 24 h, respectively).
Statistical analysis of PK parameters
Correlation of body weight with total clearance and other PK values was performed by Spearman's correlation and expressed via Spearman's correlation coefficient. Two-sided p-values <0.05 were considered as statistically significant.
Results
Patients
Nine intensive care patients with acute renal failure and proven or suspected CMV infection were included in this study. Detailed patients´ characteristics are listed in table S1. All patients were anuric and had no additional diuresis. Mean age (mean ± SD) was 56 ± 9 years and mean body weight was 86 ± 25 kg. All patients were mechanically ventilated and mean SAPS II score (severity of disease classification system) was 62 ± 13. None of these patients received imipenem, mycophenolate, probenecid, tenofovir or zidovudine, which are known to possibly enhance toxic effects of ganciclovir. [5, 17] None of these patients had a known hypersensitivity or intolerance to the substance ganciclovir.
Ganciclovir serum levels
Ganciclovir was administered to all patients in a dosage of 5 mg/kg per day. The mean concentration time course of ganciclovir (levels drawn from the prefilter and postfilter line of the extracorporeal circuit and from the ultradiafiltrate) is illustrated in Figure 1 . The mean peak plasma concentration after infusion was 11.8 ± 3.5 mg/L at the prefilter port and 10.9 ± 3 mg/L at the postfilter port. Mean trough plasma concentration was 2.4 ± 0.7 mg/L at the prefilter port 
Model-based simulations
Simulations of arterial ganciclovir concentrations on additional six days of dosing in the underlying nine patients showed that nearly every patient exceeded the anticipated trough-level As with the study population, AUC-adjusted dosing resulted in target-AUC values for most of the simulated patients (data not shown), but often the trough-concentrations were under the threshold of 2 mg/L. Trough levels were extremely low, almost reaching zero in the third course (see Figure 4D ).
Statistical analysis of PK values
Body weight correlated significantly with total clearance (r = 0.92, p < 0.005) and volume of distribution (r = 0.75, p < 0.05). Furthermore body weight correlated with minimal drug serum concentration (C min / C 24 ) (r = 0.68, p < 0.05) but not with drug exposure by means of AUC (p = n.s.).
Discussion
Ganciclovir is an effective antiviral substance used for first-line treatment in CMV infections, which has a predominantly renal elimination. [1, 3, 5, 19] Although ganciclovir is often used in clinical routine, pharmacokinetic data in critically ill patients undergoing CRRT are rare and inconsistent. Up to date, only two case reports of pharmacokinetic properties of ganciclovir in patients receiving CVVHDF are published. [20, 21] All study patients reached an AUC above the target of 50 mg·h/L in the simulated ganciclovir courses. Nearly all patients with body weight-adjusted dosing exceeded the target trough level.
Interindividual variability of the AUC could be reduced in the individualized dosing approach using target-AUC. However, trough concentrations systematically fell below the anticipated value of 2 mg/L in this cohort. These findings were confirmed in a Monte Carlo simulation of 1000 new patients. Solely the lowest simulated dosage of 1.5 mg/kg/12h did not result in adequate exposure by means of AUC.
Based on these findings, bodyweight-based dosing seems to be superior over AUC-adjusted dosing, as long as no clear clinical relevant AUC value is defined. With a ganciclovir dose of 2.5
and 5 mg/kg/24h AUC values above 50 mg·h/L and trough concentrations above 2 mg/L could be achieved in the simulations of additional courses for most of the nine patients, whereas in the Monte Carlo simulations AUC-based dosing lead to extremely low ganciclovir trough-levels (close to zero) in some patients (see Fig. 4D ). Therefore, with respect to a target-AUC of 50 mg·h/L and a ganciclovir trough-level of 2 mg/L the majority of patients would be sufficiently dosed with 2.5 mg/kg/24h.
Caldes et al., who also focused on target-AUC, indicated that pharmacokinetic parameters, especially total clearance (Cl tot ), were not related to body weight and therefore variability in renal function is more relevant than differences in body weight.
[10] In contrast to his assumption, we observed a significant correlation between bodyweight, total clearance and volume of distribution in our anuric patients. However, it has to be mentioned that Caldes et al.
estimated clearance based on a mean population body weight of 66.2 kg, whereas in the present Monte Carlo simultions patients with a weight between 40 and 140 kg were randomly generated.
Furthermore, as sieving coefficient (which was the same for everyone) is related to drug clearance, among patients undergoing CVVHDF, it may be assumed that Cl tot and Cl CVVHDF are on October 23, 2017 by guest http://aac.asm.org/ closely correlated and therefore weight based dosing is not needed. However, we did not detect a significant correlation between Cl tot and Cl CVVHDF (see Fig. S1 ), which may be due to the large variability of Cl tot in our dataset. As at steady state, the product of rate constant k ss and the volume of distribution may be defined as the total body clearance (Cl tot = k ss . Limitations of this study are the small number of patients and thus the lack of reliable covariates in the underlying pharmacokinetic model, e.g. covariates on clearance. However, this is a common number of patients in pharmacokinetic studies in critically ill patients with CRRT [15, 16, 24] . Furthermore, we used one type of filter (AN 69 HF hollow fiber haemofilter) and CVVHDF calibration (blood flow rate, ultrafiltration rate). Since this is a frequently used modern filter-type with a commonly used blood flow rate, other filter-types or flow rate conditions were not tested.
In conclusion, body weight dosing of ganciclovir was feasible in critically ill patients undergoing. Larger studies should be performed to confirm the optimal dosage, especially the impact of individualized dosing regimens. Based on our population pharmacokinetic simulations, with respect to a target area under the curve of 50 mg·h/L and a trough level of 2 mg/L a daily ganciclovir dose of 2.5 mg/kg seems to be adequate for anuric patients during CVVHDF. 
